HDAC9 and breast carcinoma: In order to determine if PCI-24781 is a breast cancer-specific drug or a broad-spectrum anti-tumor drug, we measured the half maximal inhibitory concentrations (IC50) of PCI-24781 and the HDAC inhibitor TSA in several tumor cell lines, including primary breast cancer cells.